RARE Earnings

Quarterly EPS
$-1.40
Q3 2024
$-1.39
Q4 2024
$-1.57
Q1 2025
$-1.17
Q2 2025
$-1.81
Q3 2025
$-1.29
Q4 2025
$-1.84
Q1 2026
$-0.90
Q2 2026
Latest Revenue214.0M
Latest Net Income-92000000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.90214.0M-92000000+28.1%+23.1%
Q1 2026-$1.84136.0M-185000000-2.2%-17.2%
Q4 2025-$1.29207.3M-128556000+25.9%+7.2%
Q3 2025-$1.81159.9M-180413000+14.7%-29.3%
Q2 2025-$1.17167.0M-115000000+13.6%+23.0%
Q1 2025-$1.57139.0M-151000000+27.7%+22.7%
Q4 2024-$1.39164.6M-133202000+29.2%+8.6%
Q3 2024-$1.40139.5M-133516000+42.3%+37.2%
Q2 2024-$1.52147.0M-131598000
Q1 2024-$2.03108.8M-170684000
Q4 2023-$1.52127.4M-123190000
Q3 2023-$2.2398.1M-159649000
Ultragenyx Pharmaceutical (RARE) — Earnings